Equities research analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post $74.47 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Crispr Therapeutics’ earnings, with the lowest sales estimate coming in at $70.00 million and the highest estimate coming in at $76.70 million. Crispr Therapeutics reported sales of $120,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 61,958.3%. The company is scheduled to issue its next quarterly earnings results on Monday, February 24th.

On average, analysts expect that Crispr Therapeutics will report full-year sales of $287.04 million for the current year, with estimates ranging from $282.57 million to $289.27 million. For the next financial year, analysts forecast that the business will report sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million.

CRSP has been the topic of several research analyst reports. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Roth Capital lifted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Finally, Canaccord Genuity lifted their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $75.95.

In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. NEXT Financial Group Inc lifted its holdings in Crispr Therapeutics by 915.0% in the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics in the 3rd quarter worth approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in Crispr Therapeutics in the 4th quarter worth approximately $26,000. Webster Bank N. A. acquired a new stake in Crispr Therapeutics in the 4th quarter worth approximately $26,000. Finally, US Bancorp DE lifted its holdings in Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares during the last quarter. Hedge funds and other institutional investors own 49.83% of the company’s stock.

NASDAQ:CRSP traded down $1.82 on Friday, hitting $56.57. 1,032,126 shares of the company’s stock traded hands, compared to its average volume of 1,104,019. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 1 year low of $29.34 and a 1 year high of $74.00. The firm has a 50-day moving average price of $63.51 and a 200-day moving average price of $52.46. The company has a market cap of $3.21 billion, a PE ratio of -122.98 and a beta of 3.20.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: Closed-End Mutual Funds

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Source link